Pfizer Inc.

PFE · NYSE · Healthcare · Drug Manufacturers General

Next earnings: November 3, 2026 · before the open

$28.67+0.9%Sep 25 close

1M: +2.5%
6M: +9.7%
1Y: +29.1%
5Y: -15.5%

Pfizer develops, makes and sells prescription medicines and vaccines, and earns additional fees and royalties from manufacturing and commercial partnerships.

Pfizer Inc. (PFE) stock — is it a good business? — InspectStocks

Pfizer Inc.

PFE · NYSE · Healthcare · Drug Manufacturers General

Next earnings: November 3, 2026 · before the open

$28.67+0.9%Sep 25 close

1M: +2.5%
6M: +9.7%
1Y: +29.1%
5Y: -15.5%

Compare

Pfizer develops, makes and sells prescription medicines and vaccines, and earns additional fees and royalties from manufacturing and commercial partnerships.

How it makes money

Sales of its medicines and vaccines95%
Royalties3%
Contract manufacturing and drug ingredients2%
Research and development services0%

Shares of revenue are estimates for year ended December 31, 2025, high confidence, not figures from a filing.

Competes with

What it sells6

Eliquis
A prescription medicine that helps prevent blood clots and strokes in certain patients. Pfizer shares its development and commercial profits with Bristol Myers Squibb.
Pfizer vaccine portfolio
Vaccines include the Prevnar family for pneumococcal disease, Comirnaty to help prevent coronavirus disease, and Abrysvo for respiratory syncytial virus.
Paxlovid
A prescription medicine used to treat coronavirus disease.

Show 3 more

Oncology medicines
Cancer medicines include Ibrance for breast cancer, Padcev for bladder cancer, and Xtandi for prostate cancer.
Nurtec ODT and Vydura
Migraine medicines. ODT means orally disintegrating tablet.
Vyndaqel family
Medicines for transthyretin amyloidosis, a disease in which an abnormal protein builds up in the body and can damage the heart or nerves.

Who buys it4

Wholesalers, which buy prescription medicines for resale to pharmacies, hospitals and other providers.
Retailers, pharmacies, hospitals and clinics, which buy medicines directly for patients or for use in care.
Government agencies and health institutions, which buy vaccines and medicines through contracts or purchasing programs.
Insurers and pharmacy benefit managers, which negotiate rebates and decide which medicines are covered or preferred on their drug lists.

What it stands on, and what could break it

What the business leans on

1Revenue depends on continued sales of major medicines and vaccines; generic competition after patent or regulatory exclusivity ends can reduce sales.
2Some important products rely on partnerships: Pfizer shares profits from Comirnaty with BioNTech and from Eliquis with Bristol Myers Squibb, among other collaborations.
3Sales depend on wholesalers and other distribution channels, and on insurers and pharmacy benefit managers covering products and setting their place on medicine lists.
4Pfizer buys raw materials from suppliers worldwide and relies on manufacturing sites and supply chains to make and deliver products.

What could go wrong

1When patent protection or regulatory exclusivity ends, generic or biosimilar manufacturers can sell lower-priced alternatives. Pfizer says competition can quickly reduce sales of affected products.
2Government price-setting, required rebates and insurer demands can lower the prices Pfizer receives or limit access to its medicines. The Medicare price-negotiation program now sets a price Pfizer must offer for Eliquis.
3Drug development and regulatory approval can fail or change. Pfizer reported that a late-stage study of its investigational cancer medicine sigvotatug vedotin did not meet its main survival goal, and that it withdrew Oxbryta from the United States market after reviewing clinical and registry data.

Full financial statements →

How it compares with its industry

Three ratings, each a percentile against the 21 companies we cover in Drug Manufacturers General. Deliberately kept apart rather than blended into one score — cheap, rising and well-run are three different facts, and a single number would hide which one is which.

Momentum

42of 100 in its industry

Middle of its industry

12 months to a month ago21.6%

6 months to a month ago9.1%

The most recent month is left out on purpose: returns tend to persist over 7–12 months and the newest one tends to reverse. This describes what the price has done, and says nothing about what it will do.

Value

61of 100 in its industry

Above most of its industry

Profit for the price2.65%

Cash for the price6.72%

Sales for the price38.98%

Assets for the price52.92%

Operating profit for the whole business—

Yields, so higher means cheaper — a loss-making company ranks last instead of dropping out. Cheap is not the same as good: a high yield is often a price that fell for a reason. Blended from 4 of 5 measures.

Capital allocation

2/3Mostly disciplined

3 checks not reported

Return on capital—

Shareholder yield0.00%

Share count, 3 years-0.6%

Net debt / EBITDA—

Insiders, 12 months—

What management does with the money — scored on whatever the filings answer, never as a share of the total.

The six capital-allocation checks

Return on the money investedNot enough reported to work it out
Debt against earningsNo comparable earnings to measure debt against
Cash returned to shareholdersKeeps essentially all of it
Share count over three yearsShare count 0.6% lower over three years
Payouts covered by cash flowFree cash flow covers what it pays out
Open-market insider buyingNo open-market insider dealing on file

A description of where this company sits among its competitors, not a recommendation. Ratings updated Sep 26, 2026.

About Pfizer Inc.

Pfizer discovers, tests, manufactures, markets and sells medicines and vaccines around the world. Its products address conditions including cancer, heart and blood-vessel diseases, migraine, infections, immune disorders and rare diseases. It also makes medicines and drug ingredients for other companies and is winding down a research-services business for biotechnology companies.

Head office: New York City, New York
Founded: 1849 (company founded, high confidence)
Employees: 75,000 (December 31, 2025, high confidence)
Listed on: NYSE
Financial year ends: December 31

Built from Pfizer Inc.’s own filings with the SEC. Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.

How it makes money

Sales of its medicines and vaccines95%
Royalties3%
Contract manufacturing and drug ingredients2%
Research and development services0%

Shares of revenue are estimates for year ended December 31, 2025, high confidence, not figures from a filing.

Competes with

What it sells6

Eliquis
A prescription medicine that helps prevent blood clots and strokes in certain patients. Pfizer shares its development and commercial profits with Bristol Myers Squibb.
Pfizer vaccine portfolio
Vaccines include the Prevnar family for pneumococcal disease, Comirnaty to help prevent coronavirus disease, and Abrysvo for respiratory syncytial virus.
Paxlovid
A prescription medicine used to treat coronavirus disease.

Show 3 more

Oncology medicines
Cancer medicines include Ibrance for breast cancer, Padcev for bladder cancer, and Xtandi for prostate cancer.
Nurtec ODT and Vydura
Migraine medicines. ODT means orally disintegrating tablet.
Vyndaqel family
Medicines for transthyretin amyloidosis, a disease in which an abnormal protein builds up in the body and can damage the heart or nerves.

Who buys it4

Wholesalers, which buy prescription medicines for resale to pharmacies, hospitals and other providers.
Retailers, pharmacies, hospitals and clinics, which buy medicines directly for patients or for use in care.
Government agencies and health institutions, which buy vaccines and medicines through contracts or purchasing programs.
Insurers and pharmacy benefit managers, which negotiate rebates and decide which medicines are covered or preferred on their drug lists.

What it stands on, and what could break it

What the business leans on

1Revenue depends on continued sales of major medicines and vaccines; generic competition after patent or regulatory exclusivity ends can reduce sales.
2Some important products rely on partnerships: Pfizer shares profits from Comirnaty with BioNTech and from Eliquis with Bristol Myers Squibb, among other collaborations.
3Sales depend on wholesalers and other distribution channels, and on insurers and pharmacy benefit managers covering products and setting their place on medicine lists.
4Pfizer buys raw materials from suppliers worldwide and relies on manufacturing sites and supply chains to make and deliver products.

What could go wrong

1When patent protection or regulatory exclusivity ends, generic or biosimilar manufacturers can sell lower-priced alternatives. Pfizer says competition can quickly reduce sales of affected products.
2Government price-setting, required rebates and insurer demands can lower the prices Pfizer receives or limit access to its medicines. The Medicare price-negotiation program now sets a price Pfizer must offer for Eliquis.
3Drug development and regulatory approval can fail or change. Pfizer reported that a late-stage study of its investigational cancer medicine sigvotatug vedotin did not meet its main survival goal, and that it withdrew Oxbryta from the United States market after reviewing clinical and registry data.

Full financial statements →

How it compares with its industry

Momentum

42of 100 in its industry

Middle of its industry

12 months to a month ago21.6%

6 months to a month ago9.1%

Value

61of 100 in its industry

Above most of its industry

Profit for the price2.65%

Cash for the price6.72%

Sales for the price38.98%

Assets for the price52.92%

Operating profit for the whole business—

Capital allocation

2/3Mostly disciplined

3 checks not reported

Return on capital—

Shareholder yield0.00%

Share count, 3 years-0.6%

Net debt / EBITDA—

Insiders, 12 months—

What management does with the money — scored on whatever the filings answer, never as a share of the total.

The six capital-allocation checks

Return on the money investedNot enough reported to work it out
Debt against earningsNo comparable earnings to measure debt against
Cash returned to shareholdersKeeps essentially all of it
Share count over three yearsShare count 0.6% lower over three years
Payouts covered by cash flowFree cash flow covers what it pays out
Open-market insider buyingNo open-market insider dealing on file

A description of where this company sits among its competitors, not a recommendation. Ratings updated Sep 26, 2026.

About Pfizer Inc.

Head office: New York City, New York
Founded: 1849 (company founded, high confidence)
Employees: 75,000 (December 31, 2025, high confidence)
Listed on: NYSE
Financial year ends: December 31

How it makes money

Competes with

What it sells6

Who buys it4

What it stands on, and what could break it

What the business leans on

What could go wrong

How it compares with its industry

About Pfizer Inc.

How it makes money

Competes with

What it sells6

Who buys it4

What it stands on, and what could break it

What the business leans on

What could go wrong

How it compares with its industry

About Pfizer Inc.

Growth & cash — 4 of 5